USPTO Examiner HUI SAN MING R - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18932827PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEOctober 2024May 2025Allow620YesNo
18660698ANTICANCER COMPOSITIONSMay 2024April 2025Allow1120NoNo
18636148METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASEApril 2024August 2024Allow410NoNo
18444104ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESINFebruary 2024June 2024Allow410NoNo
18411576PSILOCIN MUCATEJanuary 2024August 2024Allow711NoNo
18402989ETHYL 3-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]PROPANOATE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024March 2024Allow300NoNo
183856488-(3-BROMOBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023January 2024Allow300NoNo
18494554Dosing Regimens for ElagolixOctober 2023May 2025Allow1910NoNo
18482456COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSOctober 2023February 2025Abandon1630NoNo
18481539RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOFOctober 2023April 2025Allow1810NoNo
18474990Colonic Microbiota Responsive Polymer And Its Preparation Method And UseSeptember 2023September 2024Allow1100NoNo
18467705COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSSeptember 2023May 2024Abandon810NoNo
18462054Methods of Administering ElagolixSeptember 2023March 2024Allow610NoNo
18234232METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASEAugust 2023February 2024Allow610NoNo
18347393ESKETAMINE FOR THE TREATMENT OF DEPRESSIONJuly 2023December 2024Abandon1830NoNo
18340067STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONEJune 2023February 2025Allow2041NoNo
18336476MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGENJune 2023April 2025Allow2210NoNo
18205634METHODS FOR TREATING GI TRACT DISORDERSJune 2023June 2025Abandon2410NoNo
18200152PROGESTOGEN-ONLY ORAL CONTRACEPTIONMay 2023June 2025Allow2510NoNo
18318210COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONMay 2023March 2024Abandon1010NoNo
18316553COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONMay 2023March 2024Abandon1010NoNo
18315706COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONMay 2023March 2024Abandon1010NoNo
18310755COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONMay 2023March 2024Abandon1010NoNo
18307048GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEXApril 2023February 2024Allow1010NoNo
18296851COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONApril 2023March 2024Abandon1110NoNo
18129177METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSUREMarch 2023February 2025Allow2310NoNo
18194257COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSIONMarch 2023March 2024Abandon1120NoNo
18192244ANTICANCER COMPOSITIONSMarch 2023March 2025Abandon2410NoNo
18177585COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSMarch 2023August 2023Allow610NoNo
18171790METHODS OF TREATING TESTOSTERONE DEFICIENCYFebruary 2023May 2024Abandon1520YesNo
18171077ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESINFebruary 2023December 2023Allow1011NoNo
18092688METHODS FOR TREATMENT OF PARKINSON'S DISEASEJanuary 2023July 2023Allow610NoNo
18091510COMPOSITIONS THAT PREFERENTIALLY POTENTIATE SUBTYPES OF GABAA RECEPTORS AND METHODS OF USE THEREOFDecember 2022April 2025Abandon2810NoNo
18077279NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOFDecember 2022May 2025Abandon3010NoNo
18062764Method of Adjuvant Cancer TreatmentDecember 2022May 2025Abandon2910NoNo
18059554SPIRO-OXAZOLONESNovember 2022July 2024Allow1900NoNo
18059924DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASESNovember 2022January 2024Allow1410NoNo
18053478PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASESNovember 2022October 2023Allow1100NoNo
18053248COMPOSITIONS FOR IMPROVING SEXUAL FUNCTIONNovember 2022February 2025Abandon2710NoNo
17963712COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMSOctober 2022March 2023Allow510NoNo
17937934Oral Allopregnanolone Compositions and Methods of UseOctober 2022November 2024Allow2641NoNo
17952238Dry Powder Foamable Formulations for Delivery of Medicaments through the MucosaSeptember 2022June 2023Allow811YesNo
17934889BORTEZOMIB COMPOSITIONSSeptember 2022April 2023Allow610NoNo
17950785RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOFSeptember 2022August 2024Allow2301NoNo
17945865METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORSSeptember 2022March 2025Abandon3031NoNo
17901078DOPA DECARBOXYLASE INHIBITOR COMPOSITIONSSeptember 2022June 2025Abandon3301NoNo
17823559TARGETING PAPAIN-LIKE PROTEASE FOR BROAD-SPECTRUM CORONAVIRUSES INHIBITIONAugust 2022January 2024Allow1620NoNo
17823080Oral Allopregnanolone Compositions and Methods of UseAugust 2022March 2024Allow1821NoNo
17893999COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMSAugust 2022May 2025Allow3310NoNo
17821342BUPROPION AS A MODULATOR OF DRUG ACTIVITYAugust 2022February 2023Allow620NoNo
17819858CHIRAL DIARYL MACROCYCLES AND USES THEREOFAugust 2022January 2025Allow2920NoNo
17814591FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITHJuly 2022March 2025Abandon3210NoNo
17813619COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMSJuly 2022October 2024Abandon2710NoNo
17809192AQUEOUS ORAL PHARMACEUTICAL SUSPENSION COMPOSITIONSJune 2022September 2024Allow2710NoNo
17846806TANNIN FORMULATIONS FOR AGRICULTURAL USE IN PLANTSJune 2022December 2024Abandon3040YesNo
17846322VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACTJune 2022April 2025Abandon3410NoNo
17845459TANNIN FORMULATIONS FOR AGRICULTURAL USE IN PLANTSJune 2022June 2024Allow2340YesNo
17845105DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINEJune 2022March 2024Allow2110NoNo
17843506MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USEJune 2022October 2024Abandon2810NoNo
17840203CYPROTERONE ACETATE COMPOSITIONS AND USES THEREOFJune 2022April 2025Abandon3410NoNo
17806526INJECTABLE FORMULATIONSJune 2022March 2025Allow3320NoNo
17836120PROSTACYCLIN ANALOGUE FORMULATIONSJune 2022December 2024Abandon3020NoNo
17824288PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGSMay 2022June 2025Allow3611NoNo
17778953CURCUMIN COMPOSITIONS FOR OSTEOARTHRITIS AND JOINT WELLNESSMay 2022June 2025Allow3701NoNo
17745662COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATIONMay 2022March 2025Abandon3411NoNo
17742665ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOFMay 2022June 2024Abandon2501NoNo
17740698DOPA DECARBOXYLASE INHIBITOR COMPOSITIONSMay 2022May 2024Abandon2410NoNo
17740673Compositions and Methods for Treating CNS DisordersMay 2022August 2022Allow310NoNo
17736494METHOD FOR TREATMENT OF PARKINSON'S DISEASEMay 2022August 2022Allow310NoNo
17720777METHOD FOR TREATMENT OF PARKINSON'S DISEASEApril 2022December 2024Abandon3210NoNo
17715133DUAL ACTIVE INSECTICIDAL COMPOSITIONSApril 2022August 2023Allow1710NoNo
177159111-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOFApril 2022April 2025Allow3621NoNo
17655483ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOFMarch 2022December 2023Allow2110NoNo
17698361METHODS OF TREATING COVID-19March 2022April 2025Abandon3711NoNo
17653950Use of Isoxazoline Derivatives for the Treatment or Prevention of Arthropod Infestations in PoultryMarch 2022June 2024Allow2811NoNo
17689576PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASESMarch 2022September 2023Allow1810NoNo
17684579METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOFMarch 2022November 2024Allow3211NoNo
17683624GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEXMarch 2022April 2023Allow1330YesNo
17639206INDUSTRIAL PROCESS FOR THE PREPARATION OF HIGH PURITY ESTETROLFebruary 2022February 2023Allow1200NoNo
17637859TREATMENT OF MENSTRUAL CYCLE-INDUCED SYMPTOMSFebruary 2022November 2022Allow810NoNo
17651877AQUEOUS ORAL PHARMACEUTICAL SUSPENSION COMPOSITIONSFebruary 2022May 2022Allow300NoNo
17590784Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimenFebruary 2022February 2024Allow2400NoNo
17586942Methods of Administering ElagolixJanuary 2022June 2024Abandon2810NoNo
17580954Pharmaceutical Compositions Comprising a Hydroxyethylquercetin GlucuronideJanuary 2022June 2024Abandon2801NoNo
17581818USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSISJanuary 2022May 2024Allow2710NoNo
17581030TANNIN FORMULATIONS FOR AGRICULTURAL USE IN PLANTSJanuary 2022May 2022Allow310NoNo
17579263METHODS AND COMPOSITIONS FOR TREATING CANCERJanuary 2022February 2024Abandon2510NoNo
17567473METHOD FOR TREATMENT OF PARKINSON'S DISEASEJanuary 2022April 2022Allow310NoNo
17644491COMBINATION OF PI3K INHIBITOR AND C-MET INHIBITORDecember 2021January 2024Abandon2510NoNo
17550253LEVOTHYROXINE LIQUID FORMULATIONSDecember 2021December 2023Abandon2410NoNo
17547720PROGESTERONE RECEPTOR ANTAGONIST DOSAGE FORMDecember 2021December 2023Abandon2410NoNo
17542855TOPICAL CORTICOSTEROIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACTDecember 2021July 2024Abandon3110NoNo
17533984METHOD FOR TREATMENT OF PARKINSON'S DISEASENovember 2021July 2024Abandon3210NoNo
17526493COMPOSITIONS COMPRISING OXYGENATED CHOLESTEROL SULFATE AND AT LEAST ONE OF POLYALKYLENE GLYCOL, CARBOXYMETHYL CELLULOSE AND POLYOXYLGLYCERIDENovember 2021June 2024Abandon3120NoNo
17610236PHARMACEUTICAL COMPOSITION CONTAINING BREXANOLONE, GANAXOLONE, OR ZURANOLONE, AND USE THEREOFNovember 2021April 2025Allow4111NoNo
17515945PROPHYLACTIC AND THERAPEUTIC DRUG FOR NONALCOHOLIC FATTY LIVER DISEASENovember 2021March 2024Allow2811NoNo
17607867New Kaurane analogues, their preparation and therapeutically usesOctober 2021April 2025Abandon4110NoNo
17513946THERAPEUTIC AGENT FOR FIBROSISOctober 2021February 2023Allow1600NoNo
17513199METHODS FOR TREATING VITILIGO LESIONS HAVING IMPROVED EFFICACYOctober 2021December 2023Abandon2610NoNo
17508951TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTIONOctober 2021June 2024Allow3221YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUI, SAN MING R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.3%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
16
Allowed After Appeal Filing
2
(12.5%)
Not Allowed After Appeal Filing
14
(87.5%)
Filing Benefit Percentile
12.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HUI, SAN MING R - Prosecution Strategy Guide

Executive Summary

Examiner HUI, SAN MING R works in Art Unit 1627 and has examined 445 patent applications in our dataset. With an allowance rate of 65.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner HUI, SAN MING R's allowance rate of 65.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HUI, SAN MING R receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HUI, SAN MING R is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.5% benefit to allowance rate for applications examined by HUI, SAN MING R. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 52% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 48.0% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 81.8% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 26.1% are granted (fully or in part). This grant rate is in the 17% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.6% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.